Abstract
The first clinical studies on the use of electrochemotherapy to treat liver tumours that were not amenable to surgery or thermal ablation techniques have recently been published. However, there is still a lack of data on the effects of electrochemotherapy on normal liver tissue. Therefore, we designed a translational animal model study to test whether electrochemotherapy with bleomycin causes clinically significant damage to normal liver tissue, with emphasis on large blood vessels and bile ducts. We performed electrochemotherapy with bleomycin or delivered electric pulses alone using a potentially risky treatment strategy in eight pigs. Two and seven days after treatment, livers were explanted, and histological analysis was performed. Blood samples were collected before treatment and again before euthanasia to evaluate blood biomarkers of liver function and systemic inflammatory response. We found no thrombosis or other clinically significant damage to large blood vessels and bile ducts in the liver. No clinical or laboratory findings suggested impaired liver function or systemic inflammatory response. Electrochemotherapy with bleomycin does not cause clinically significant damage to normal liver tissue. Our study provides further evidence that electrochemotherapy with bleomycin is safe for treatment of patients with tumours near large blood vessels in the liver.
Highlights
Electrochemotherapy (ECT) is a tumour treatment method that combines the use of electric pulses with cytotoxic drugs[1]
No complications were detected related to electrode insertion, electric pulse delivery, or bleomycin administration
The primary aim of our animal model study was to evaluate the histological changes in the liver induced by ECT with bleomycin
Summary
Electrochemotherapy (ECT) is a tumour treatment method that combines the use of electric pulses with cytotoxic drugs[1]. Because of its nonthermal mechanism of action, deep-seated ECT is currently performed primarily for tumours near large blood vessels and other vital structures where no other treatment is possible due to the risk of serious complications[12,18]. To determine whether ECT with bleomycin causes clinically significant damage to normal liver tissue with respect to large blood vessels and bile ducts, we designed a translational animal model study to investigate the effects of potentially risky ECT treatment strategies. Based on our previous findings in laboratory mouse studies and human clinical trials, we hypothesized that ECT with bleomycin will not cause clinically significant damage to normal liver tissue, and that no treatment effects on liver function and/or systemic inflammatory response will be observed[6,12,14,17]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.